Sanofi (Austria)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria

Louis Boiron, Elmar A. Joura, Nathalie Largeron et al. · BMC Infectious Diseases · 2016 · 46 citations · Full text

Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis

Xavier Bresse, Christoph Goergen, Bernhard Prager et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2014 · 36 citations

Efficacy and tolerability of alirocumab in Austrian clinical practice – results of the non-interventional PEARL-AT study

Deborah R. Leitner, Hermann Toplak, Ludmilla Kedenko et al. · Current Medical Research and Opinion · 2020 · 14 citations · Full text

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

Monika Lechleitner, Michael Roden, E. Haehling et al. · Wiener klinische Wochenschrift · 2005 · 10 citations

Diabetes Management, Insulin Glargine, Insulin Management +8